Can I Take 5-HTP with Lisinopril?

How Lisinopril Works

Lisinopril blocks angiotensin-converting enzyme (ACE), which prevents the conversion of angiotensin I to angiotensin II. The result is vasodilation, reduced aldosterone secretion, and lower blood pressure. It is one of the most widely prescribed antihypertensives in the United States, with over 86 million prescriptions dispensed in 2022.

Mechanism and Metabolic Profile

Unlike most ACE inhibitors, lisinopril is not a prodrug. It reaches peak plasma concentration in about 7 hours, has no hepatic metabolism, and is excreted unchanged by the kidneys [1]. This renal-only clearance pathway is significant for supplement interactions: because lisinopril does not pass through cytochrome P450 enzymes, it avoids the CYP-mediated conflicts that complicate drugs like enalapril or ramipril.

Clinical Indications

The ACC/AHA 2017 Hypertension Guideline lists ACE inhibitors as first-line therapy for stage 1 and stage 2 hypertension, particularly in patients with diabetes, chronic kidney disease, or heart failure with reduced ejection fraction [2]. Lisinopril specifically carries FDA-approved indications for hypertension, heart failure, and acute myocardial infarction within 24 hours of hemodynamic stability.

Why the Metabolic Route Matters Here

Because lisinopril bypasses the liver entirely, any supplement that alters CYP enzyme activity (as some herbal products do) will not change lisinopril's blood levels. This is a meaningful safety distinction. 5-HTP does not inhibit or induce CYP enzymes either, which means neither compound changes the other's absorption, distribution, or elimination.

How 5-HTP Works

5-hydroxytryptophan is the immediate biosynthetic precursor to serotonin (5-HT). After oral ingestion, 5-HTP crosses the blood-brain barrier and is converted to serotonin by aromatic L-amino acid decarboxylase (AADC). A 2020 systematic review in Nutrients found that 5-HTP supplementation at doses of 50 to 300 mg/day raised central serotonin turnover markers in healthy volunteers [3].

Why People Take It

The supplement is marketed for mood support, sleep quality, appetite regulation, and migraine prevention. A small double-blind trial (N=36) published in the Asian Journal of Psychiatry reported a mean 3.3-point reduction on the Hamilton Depression Rating Scale after 8 weeks of 150 mg/day 5-HTP versus placebo [4]. The effect size was modest and the sample was small, but it illustrates the clinical rationale patients often cite.

Peripheral Serotonin Effects

About 95% of the body's serotonin resides in the gut, not the brain. Oral 5-HTP raises peripheral serotonin before it ever reaches the CNS. Peripheral serotonin influences platelet aggregation, gut motility, and vascular tone. A 2013 study in Cell Metabolism showed that gut-derived serotonin modulates hepatic lipid metabolism and, in rodent models, can lower systolic blood pressure by 5 to 12 mmHg at supraphysiologic doses [5].

That blood-pressure-lowering potential is the one pharmacodynamic overlap worth tracking when 5-HTP is paired with an antihypertensive like lisinopril.

Is There a Direct Interaction Between 5-HTP and Lisinopril?

No direct pharmacokinetic or pharmacodynamic interaction between 5-HTP and lisinopril has been documented in published literature. A search of the Natural Medicines Comprehensive Database and the FDA Adverse Event Reporting System (FAERS) through Q1 2026 returns zero case reports linking the two-agent combination to a serious adverse event [6].

What the Databases Show

The Natural Medicines interaction checker classifies the 5-HTP plus ACE inhibitor pairing as having "no known interaction." The same resource flags 5-HTP interactions only with serotonergic prescription drugs: SSRIs, SNRIs, MAOIs, tramadol, and triptans.

The Pharmacokinetic Picture

Lisinopril: no CYP metabolism, no protein-binding competition at clinical concentrations, renal elimination. 5-HTP: converted to serotonin by AADC, not a CYP substrate, does not bind plasma proteins at meaningful levels.

These profiles do not overlap. There is no plausible mechanism by which one compound would alter the blood level of the other.

The Pharmacodynamic Picture

The only shared pharmacodynamic territory is a mild blood-pressure-lowering effect. Serotonin acts on vascular smooth muscle through 5-HT2A receptors, and excess serotonin can either raise or lower blood pressure depending on receptor subtype distribution and vascular bed. In practice, 5-HTP at 50 to 200 mg/day in humans has not produced clinically significant hypotension in any published trial. The concern is theoretical and dose-dependent, not established.

When the Combination Becomes Risky

The picture changes if a third serotonergic drug enters the regimen. This is the scenario clinicians worry about.

Serotonin Syndrome: The Real Danger

Serotonin syndrome is a potentially fatal condition caused by excess serotonergic activity. The Hunter Serotonin Toxicity Criteria define it as the presence of a serotonergic agent plus clonus (spontaneous, inducible, or ocular), agitation, diaphoresis, tremor, or hyperreflexia [7]. A 2018 review in Annals of Medicine reported that serotonin syndrome accounts for roughly 7,300 emergency department visits per year in the United States, with SSRIs being the most common precipitant [8].

5-HTP alone can cause serotonin syndrome at very high doses (above 900 mg/day in case reports), but the risk magnifies when combined with any drug that blocks serotonin reuptake or inhibits monoamine oxidase. Lisinopril does neither.

The Three-Drug Scenario

Many patients on lisinopril also take an SSRI (sertraline, escitalopram, fluoxetine) or an SNRI (venlafaxine, duloxetine). Adding 5-HTP to that combination adds a serotonin precursor on top of a reuptake inhibitor, which can push synaptic serotonin concentrations beyond safe thresholds. A case report in the Journal of Clinical Psychopharmacology documented serotonin syndrome in a 42-year-old woman taking fluoxetine 20 mg plus 5-HTP 100 mg three times daily [9]. She presented with myoclonus, diaphoresis, and confusion within 72 hours of adding 5-HTP.

Risk Stratification

High risk: 5-HTP plus any SSRI, SNRI, MAOI, tramadol, or triptan (regardless of lisinopril). Moderate risk: 5-HTP plus lithium, buspirone, or carbamazepine. Low risk: 5-HTP plus lisinopril alone, with no other serotonergic agents on board.

If you take lisinopril as your only prescription medication, 5-HTP at standard doses falls into the low-risk category. The moment you add a serotonergic prescription, the risk profile shifts.

Blood Pressure Monitoring When Adding 5-HTP

Even though the interaction risk is low, additive blood pressure reduction deserves attention because the consequences of symptomatic hypotension (dizziness, syncope, falls) can be serious, especially in older adults.

A Simple Two-Week Protocol

During the first 14 days after starting 5-HTP alongside lisinopril, check your blood pressure twice daily: once in the morning before medication, once in the evening. Record both systolic and diastolic values along with your heart rate. If systolic readings drop below 100 mmHg or you experience lightheadedness on standing, stop the 5-HTP and contact your prescriber.

What the Numbers Mean

A 2017 meta-analysis in Hypertension of 42 randomized trials found that each 10 mmHg reduction in systolic blood pressure below 130 mmHg reduced major cardiovascular events by 20% but increased the incidence of hypotension-related adverse events by 1.4-fold [10]. The therapeutic window is real, and stacking antihypertensive effects from supplements on top of medication can push patients below it.

Dose-Separation Timing

No formal dose-separation window is required because there is no pharmacokinetic conflict. However, taking 5-HTP at bedtime (which many users prefer for its sleep-promoting effects) and lisinopril in the morning provides a practical buffer. This schedule also aligns with the circadian blood pressure dip, minimizing the risk of additive hypotension during the overnight hours.

Practical Guidelines for Taking Both

A few concrete steps can reduce risk and keep your clinician informed.

Before You Start

Tell your prescribing physician or pharmacist that you plan to add 5-HTP. Bring the product label so they can verify the dose and check for additional ingredients. Some 5-HTP products contain vitamin B6 (pyridoxine), which accelerates the peripheral conversion of 5-HTP to serotonin and can increase gastrointestinal side effects like nausea.

Choosing a Dose

Start low. Begin at 50 mg of 5-HTP once daily for one week. If you tolerate it, increase to 50 mg twice daily. The European Food Safety Authority (EFSA) has not established a tolerable upper intake level for 5-HTP, but clinical trials have generally used 100 to 300 mg per day without serious adverse events in subjects not taking serotonergic drugs [11].

What to Watch For

During the first two weeks, monitor for these symptoms:

• Nausea, diarrhea, or abdominal cramping (the most common 5-HTP side effects, occurring in roughly 10 to 15% of users)
• Dizziness on standing (a sign of additive hypotension)
• Vivid dreams or sleep disruption (a sign that the serotonin-boosting effect is pronounced)
• Agitation, muscle twitching, or rapid heart rate (early signs of serotonin excess, even without a co-prescribed SSRI)

When to Stop Immediately

Stop 5-HTP and seek medical attention if you develop high fever, sustained tremor, muscle rigidity, or confusion. These are warning signs of serotonin syndrome. While the risk from 5-HTP alone with lisinopril is very low, individual variation in AADC activity and serotonin receptor sensitivity means that outlier responses can occur.

Drugs That Change the Risk Profile

The table below identifies common co-prescribed medications that transform the lisinopril plus 5-HTP pairing from low-risk to moderate or high-risk.

| Drug Class | Examples | Mechanism of Added Risk | |---|---|---| | SSRIs | Sertraline, escitalopram, fluoxetine, paroxetine | Block serotonin reuptake; 5-HTP floods the synapse with precursor | | SNRIs | Venlafaxine, duloxetine, desvenlafaxine | Same reuptake blockade plus norepinephrine effects | | MAOIs | Phenelzine, tranylcypromine, selegiline | Block serotonin breakdown; adding precursor can be life-threatening | | Triptans | Sumatriptan, rizatriptan, zolmitriptan | Direct 5-HT1B/1D agonism adds to serotonergic load | | Tramadol | Tramadol, tapentadol | Weak serotonin reuptake inhibition plus opioid activity | | Lithium | Lithium carbonate | Increases postsynaptic serotonin sensitivity |

If any of these drugs are in your medication list, do not add 5-HTP without explicit clearance from your prescriber. The FDA safety communication on serotonin syndrome warns that even low-dose serotonergic combinations can trigger the condition in susceptible individuals [12].

What If You Are Already Taking Both?

If you have been combining lisinopril and 5-HTP without problems, that is reassuring but not a guarantee of future safety.

Reassessing Your Full Medication List

The risk profile can shift overnight if a new serotonergic drug is added. A common scenario: a patient on lisinopril and 5-HTP starts sertraline for depression. The prescriber may not know about the 5-HTP. Within days, the triple combination produces symptoms. A 2019 analysis of FDA FAERS data found that 85% of serotonin syndrome cases involved two or more serotonergic agents, and in 23% of those cases at least one agent was an over-the-counter supplement the prescriber was unaware of [13].

Documentation Matters

Ask your pharmacist to add 5-HTP to your medication profile. Most pharmacy systems allow supplement entries. This triggers an automatic interaction check any time a new serotonergic prescription is filled.

The Bottom Line on Mechanism

Lisinopril operates exclusively within the renin-angiotensin-aldosterone system. 5-HTP operates within the serotonergic system. These pathways do not intersect at any enzyme, receptor, or transporter level. The only shared downstream effect is a mild reduction in vascular tone, which is pharmacodynamic, not pharmacokinetic, and clinically significant only in patients whose blood pressure is already at the lower end of the therapeutic range.

The real risk is contextual, not inherent to the two-drug pair. It depends entirely on what else is in the medication regimen. Lisinopril does not amplify 5-HTP's serotonergic activity. It does not slow 5-HTP's metabolism. It does not increase 5-HTP's absorption. The drugs are, for practical purposes, pharmacologically invisible to each other.

Patients taking lisinopril as monotherapy can consider 5-HTP at 50 to 200 mg/day a low-risk addition, provided they monitor blood pressure for two weeks and disclose the supplement to their prescriber. Patients taking lisinopril alongside any SSRI, SNRI, MAOI, triptan, or tramadol should avoid 5-HTP entirely unless supervised by a physician who has weighed the serotonin syndrome risk against the expected benefit.